Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Orphan Drug

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533739

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533739

Immune Thrombocytopenia Drugs

PUBLISHED:
PAGES: 384 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Immune Thrombocytopenia Drugs Market to Reach US$3.5 Billion by 2030

The global market for Immune Thrombocytopenia Drugs estimated at US$3.3 Billion in the year 2023, is expected to reach US$3.5 Billion by 2030, growing at a CAGR of 1.0% over the analysis period 2023-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 0.9% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Intravenous Immunoglobulins segment is estimated at 1.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$891.6 Million While China is Forecast to Grow at 1.9% CAGR

The Immune Thrombocytopenia Drugs market in the U.S. is estimated at US$891.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$625.0 Million by the year 2030 trailing a CAGR of 1.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 0.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.6% CAGR.

Global Immune Thrombocytopenia Drugs Market - Key Trends and Drivers Summarized

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by the body's immune system mistakenly attacking and destroying platelets, which are essential for normal blood clotting. This condition can lead to excessive bruising, bleeding, and in severe cases, life-threatening hemorrhages. The management of ITP involves a variety of therapeutic approaches aimed at increasing platelet count and preventing bleeding episodes. The first line of treatment typically includes corticosteroids, which help suppress the immune response, and intravenous immunoglobulin (IVIG), which temporarily raises platelet levels. For patients who do not respond to these initial treatments, second-line therapies such as rituximab, a monoclonal antibody that targets B cells, and thrombopoietin receptor agonists (TPO-RAs) like eltrombopag and romiplostim, which stimulate platelet production, are commonly used. These drugs have revolutionized the treatment landscape of ITP by providing more effective and targeted options for managing the disease.

Recent advancements in the understanding of ITP pathophysiology have led to the development of newer drugs and treatment strategies that offer hope for better disease control and improved patient outcomes. Research has focused on identifying specific immune pathways and cellular targets involved in the destruction of platelets. This has led to the development of novel therapies such as fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, which works by interfering with the immune processes that lead to platelet destruction. Another promising area of research is the use of biologics that can modulate the immune system more precisely, reducing the risk of side effects associated with broad immunosuppression. Additionally, advances in personalized medicine are enabling more tailored treatment approaches based on individual patient characteristics and disease severity, enhancing the efficacy of ITP management.

The growth in the immune thrombocytopenia drugs market is driven by several factors, including the increasing prevalence of autoimmune disorders and the rising awareness and diagnosis of ITP. Technological advancements in drug development and a better understanding of the disease mechanisms have led to the introduction of more targeted and effective therapies. Consumer behavior towards seeking specialized and advanced treatments has also supported market growth, as patients and healthcare providers opt for newer, more effective treatment options. Additionally, significant investments in research and development by pharmaceutical companies and support from regulatory bodies have facilitated the approval and commercialization of innovative ITP therapies. The expansion of healthcare infrastructure, particularly in emerging markets, has increased access to advanced treatments, further driving market growth. These factors collectively ensure a dynamic and expanding market for immune thrombocytopenia drugs, aiming to improve patient outcomes and quality of life for those affected by this challenging condition.

Select Competitors (Total 51 Featured) -

  • AInos Inc.
  • Amgen Inc. (Nplate)
  • CSL Behring US Medical Affairs
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Kyowa Hakko Kirin Co., Ltd
  • Novartis Pharmaceuticals Corporation
  • Pfizer Inc.
  • Rigel Pharmaceuticals, Inc.
  • Sandoz Canada Inc.
  • Shionogi & Co., Ltd.
  • Sobi (Doptelet)
  • Teva Active Pharmaceutical Ingredients (A Division of Teva Pharmaceutical Industries Ltd.)
  • Viatris Inc.;
Show more
Product Code: MCP26815

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Immune Thrombocytopenia Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rise in Autoimmune Disorders Globally Increases Demand for ITP Therapeutics
    • Corticosteroids Remain the Drugs of Choice for Management of Acute ITP
    • Aging Population, a Key Demographic Growth Driver
    • Drug-induced Thrombocytopenia Rises in Prevalence
    • Advances in Biological Therapies Offer New Hope for ITP Patients
    • Role of Genetic Research in Understanding and Treating ITP
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Immune Thrombocytopenia Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Immune Thrombocytopenia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Immune Thrombocytopenia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Intravenous Immunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Intravenous Immunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Intravenous Immunoglobulins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Thrombopoietin Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Thrombopoietin Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Thrombopoietin Receptor Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Thrombocytopenia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Thrombocytopenia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Thrombocytopenia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Acute Immune Thrombocytopenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Acute Immune Thrombocytopenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Acute Immune Thrombocytopenia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Chronic Immune Thrombocytopenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Chronic Immune Thrombocytopenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Chronic Immune Thrombocytopenia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Specialty Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Research & Academic Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • JAPAN
    • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • CHINA
    • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • EUROPE
    • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Immune Thrombocytopenia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • FRANCE
    • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • GERMANY
    • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • INDIA
    • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: India 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: India 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Immune Thrombocytopenia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Immune Thrombocytopenia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • AFRICA
    • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!